Cartalax

Description

Cartalax Technical Overview

Cartalax is a synthetic tripeptide associated with the sequence Ala-Glu-Asp (AED). It belongs to the family of short peptide bioregulators investigated in research involving connective tissue biology, gene expression, and cellular regulation.

Cartalax has been associated with experimental studies involving cartilage-related cell systems and age-associated tissue processes.

Its defined molecular structure supports research into relationships between short peptide sequences and biological responses.

Compound Specifications

Storage and Handling

• Follow manufacturer-recommended stability conditions.
• Protect from moisture and light.
• Maintain suitable laboratory handling procedures.

Lyophilized Format

Cartalax may be supplied in lyophilized form. The actual preparation and content depend on manufacturing specifications.

Research Use Disclaimer

Cartalax is not FDA-approved for human therapeutic use. Intended exclusively for laboratory research.

Frequently Asked Questions

What Is Cartalax?

A short synthetic peptide bioregulator associated with the AED sequence.

What Is Its Amino Acid Sequence?

Ala-Glu-Asp.

How Many Residues Does It Contain?

Three.

What Research Areas Involve Cartalax?

Connective tissue cell biology, gene regulation, and short peptide research.

Research Overview

Cartalax is investigated in research concerning short peptide bioregulation and connective tissue-related cellular processes.

Connective Tissue Research

Experimental models investigate cellular responses related to tissue matrix regulation.

Gene Expression

Studies examine transcription-related biological processes.

Peptide Structure Research

The AED sequence supports molecular characterization.

Research Applications

References

1. Cartalax Peptide Scientific Literature — PubMed.

Certificate of Analysis (COA)

Documentation should establish the AED sequence, purity, and actual vial content.

Peptide Lives